Medpace Analysts Increase Their Forecasts After Upbeat Q3 Earnings

Benzinga10-24

Medpace Holdings Inc. (NASDAQ:MEDP) posted better-than-expected third-quarter earnings on Thursday.

The clinical contract research organization reported earnings of $3.86, beating the consensus of $3.52. Sales reached $659.9 million, surpassing the consensus of $640.99 million. Sales increased 23.7% year over year. On a constant currency basis, revenue jumped 23.4%.

Medpace raised fiscal 2025 earnings per share from $13.76-$14.53 to $14.60-$14.86 versus consensus of $14.07. The consensus increased 2025 sales guidance from $2.42 billion-$2.52 billion to $2.48 billion-$2.53 billion compared to the consensus of $2.46 billion.

Medpace shares rose 1% to trade at $602.08 on Friday.

These analysts made changes to their price targets on Medpace following earnings announcement.

Mizuho analyst Ann Hynes maintained Medpace with an Outperform rating and raised the price target from $575 to $655.
Barclays analyst Luke Sergott maintained the stock with an Underweight rating and raised the price target from $425 to $485.

Considering buying MEDP stock? Here’s what analysts think:

Read This Next:

Top 2 Utilities Stocks You May Want To Dump This Quarter

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2577540512?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 21:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577540512","market":"us","top_or_hot":-1,"title":"Medpace Analysts Increase Their Forecasts After Upbeat Q3 Earnings","media":"Benzinga","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/MEDP\">Medpace Holdings Inc.</a></strong> (NASDAQ:MEDP) posted better-than-expected third-quarter earnings on Thursday.</p>\n<p>The clinical contract research organization reported earnings of $3.86, beating the consensus of $3.52. Sales reached $659.9 million, surpassing the consensus of $640.99 million. Sales increased 23.7% year over year. On a constant currency basis, revenue jumped 23.4%.</p>\n<p>Medpace raised fiscal 2025 earnings per share from $13.76-$14.53 to $14.60-$14.86 versus consensus of $14.07. The consensus increased 2025 sales guidance from $2.42 billion-$2.52 billion to $2.48 billion-$2.53 billion compared to the consensus of $2.46 billion.</p>\n<p>Medpace shares rose 1% to trade at $602.08 on Friday.</p>\n<p>These analysts made changes to their price targets on Medpace following earnings announcement.</p>\n<ul>\n<li>Mizuho analyst Ann Hynes maintained Medpace with an Outperform rating and raised the price target from $575 to $655.</li>\n<li>Barclays analyst Luke Sergott maintained the stock with an Underweight rating and raised the price target from $425 to $485.</li>\n</ul>\n<p><strong>Considering buying MEDP stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"466\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/10/24095347/image-645-1024x466.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/10/24095347/image-645-1024x466.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/10/24095347/image-645-300x136.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/10/24095347/image-645-768x349.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/10/24095347/image-645.png 1126w\" width=\"1024\"/></figure>\n<p><strong>Read This Next:</strong></p>\n<ul>\n<li><strong> Top 2 Utilities Stocks You May Want To Dump This Quarter</strong></li>\n</ul>\n<p>Photo via Shutterstock</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medpace Analysts Increase Their Forecasts After Upbeat Q3 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedpace Analysts Increase Their Forecasts After Upbeat Q3 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2025-10-24 21:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/MEDP\">Medpace Holdings Inc.</a></strong> (NASDAQ:MEDP) posted better-than-expected third-quarter earnings on Thursday.</p>\n<p>The clinical contract research organization reported earnings of $3.86, beating the consensus of $3.52. Sales reached $659.9 million, surpassing the consensus of $640.99 million. Sales increased 23.7% year over year. On a constant currency basis, revenue jumped 23.4%.</p>\n<p>Medpace raised fiscal 2025 earnings per share from $13.76-$14.53 to $14.60-$14.86 versus consensus of $14.07. The consensus increased 2025 sales guidance from $2.42 billion-$2.52 billion to $2.48 billion-$2.53 billion compared to the consensus of $2.46 billion.</p>\n<p>Medpace shares rose 1% to trade at $602.08 on Friday.</p>\n<p>These analysts made changes to their price targets on Medpace following earnings announcement.</p>\n<ul>\n<li>Mizuho analyst Ann Hynes maintained Medpace with an Outperform rating and raised the price target from $575 to $655.</li>\n<li>Barclays analyst Luke Sergott maintained the stock with an Underweight rating and raised the price target from $425 to $485.</li>\n</ul>\n<p><strong>Considering buying MEDP stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"466\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/10/24095347/image-645-1024x466.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/10/24095347/image-645-1024x466.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/10/24095347/image-645-300x136.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/10/24095347/image-645-768x349.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/10/24095347/image-645.png 1126w\" width=\"1024\"/></figure>\n<p><strong>Read This Next:</strong></p>\n<ul>\n<li><strong> Top 2 Utilities Stocks You May Want To Dump This Quarter</strong></li>\n</ul>\n<p>Photo via Shutterstock</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MEDP","symbol_name":"Medpace Holdings Inc.","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/25/10/48404837/medpace-analysts-increase-their-forecasts-after-upbeat-q3-earnings","article_id":"2577540512","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577540512","pubTimestamp":1761314120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MEDP":"Medpace Holdings Inc."},"translate_title":"Medpace分析师在第三季度盈利乐观后上调预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MEDP":1.5},"content_text":"Medpace Holdings Inc. (NASDAQ:MEDP) posted better-than-expected third-quarter earnings on Thursday.\nThe clinical contract research organization reported earnings of $3.86, beating the consensus of $3.52. Sales reached $659.9 million, surpassing the consensus of $640.99 million. Sales increased 23.7% year over year. On a constant currency basis, revenue jumped 23.4%.\nMedpace raised fiscal 2025 earnings per share from $13.76-$14.53 to $14.60-$14.86 versus consensus of $14.07. The consensus increased 2025 sales guidance from $2.42 billion-$2.52 billion to $2.48 billion-$2.53 billion compared to the consensus of $2.46 billion.\nMedpace shares rose 1% to trade at $602.08 on Friday.\nThese analysts made changes to their price targets on Medpace following earnings announcement.\n\nMizuho analyst Ann Hynes maintained Medpace with an Outperform rating and raised the price target from $575 to $655.\nBarclays analyst Luke Sergott maintained the stock with an Underweight rating and raised the price target from $425 to $485.\n\nConsidering buying MEDP stock? Here’s what analysts think: \n\nRead This Next:\n\n Top 2 Utilities Stocks You May Want To Dump This Quarter\n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2577540512","isCrawlerRequest":true}